Add Yahoo as a preferred source to see more of our stories on Google. Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock.

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in triple-negative breast cancer (TNBC). Tumor-Infiltrating Lymphocytes (TILs) High ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Even when diagnosed early, triple-negative breast cancer (TNBC) has a higher mortality rate compared with other breast cancer subtypes due to its aggressive nature. However, results from the ...

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Triple-negative breast cancer (TNBC) was first described as a distinct disease ...

We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...

Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca and Daiichi Sankyo's ADC AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab ...